NCT01341106终止4 期
Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Changes of liver stiffness measurement (LSM) and hyaluronan measurement in blood
研究概览
简要总结
This study will examine whether 12 month treatment with entecavir(Baraclude®) has an effect on changes of liver stiffness measurement (LSM) and of hyaluronan measurement in patients with chronic hepatitis B infection.
详细描述
Patients with chronic hepatitis B infection and relevant liver fibrosis will be treated with entecavir during 5 years or until anti-HBs seroconversion or 6-12 months after anti-HBe seroconversion and HBeAg loss. There are 9 visits during treatment for each patient. At all visits, each patient will consent to give 20 ml blood sample for study examination and 40 ml blood sample for research purposes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •chronic hepatitis B infection with detectable HBV (hepatitis B virus)-DNA at baseline
- •results of a current liver biopsy (date of liver biopsy must not be longer than 3 months as date of screening visit)
- •detection of relevant liver fibrosis in liver histology after percutaneous or laparoscopic biopsy (histologically ≥ F2) after estimation by an experienced pathologist in the liver pathology and sufficient evaluability of the biopsy (usually evaluation of portal at least 8 fields)
- •Therapy indication according to current guidelines cHBV infection ( any virus replication in the presence of liver cirrhosis, or detection of HBV-DNA ≥ 2000 IU / ml and/or liver histology with inflammatory Grade ≥2 / fibrosis stage 2 and presence of ALT <5 x ULN)
- •non-pregnant and non-breastfeeding women, who fitful one of following criteria: * post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum FSH (follicle stimulating hormone)> 40mlU/ml)
- •6 weeks after surgical sterilization by bilateral tubal transection or after bilateral oophorectomy with or without hysterectomy
- •Correct application of two methods of sure contraception (any combination of a hormonal contraceptive (the pill, hormone IUD (intrauterine device), Depo-Provera, Implanon, contraceptive patch or vaginal ring) or IUD with a barrier contraceptive with spermicide (diaphragm, cervical cap, LEA contraceptive, female condoms or condom)or a spermicide.
- •Sexual abstinence for 2 weeks before the first administration of the study medication, during the study period and after the study during 30 days (time of elimination of study medication)
- •Patients, who have only female sexual partners
- •Male partner of a female patient, who before study inclusion, sterile and only one sexual partner of this female patient is
- •Patients willing and able to complete the requirements of this study
排除标准
- •anamnestic known hypersensitivity to Baraclude® or its ingredients or to drugs with similar chemical structure
- •Participation of patients in another clinical study within last 4 weeks prior to the inclusion or simultaneous participation in another clinical study
- •anamnestic known substance dependance or another diseases, which not allowed persons to understand essence and importance and possible consequences of the trial
- •lack of cooperation and informed consent
- •co-infection with hepatitis C, hepatitis D or HIV
- •detection of hepatocellular carcinoma
- •serious, chronic disease with an estimated prognosis for survival shorter than the study period of 5 years
- •every previous therapy with lamivudine or telbivudine or previous therapy with other antiviral substance within last 6 months before study inclusion
- •contraindications to the use of entecavir
- •creatinine clearance <50 ml / min and / or need for hemodialysis
- •MELD score >15 points and / or detection of ascites
研究组 & 干预措施
Treatment Arm
Experimental
Patients will be treated with entecavir
干预措施: Treatment with entecavir(Baraclude®) (Drug)
结局指标
主要结局
Changes of liver stiffness measurement (LSM) and hyaluronan measurement in blood
时间窗: 12 Month
Changes of liver stiffness measurement (LSM) and hyaluronan measurement in blood will be checked as markers of fibrous tissue in the liver after treatment with entecavir(Baraclude®) within 12 month.
次要结局
- Changes on Pro-Collagen-III-N-Peptid, Tissue Inhibitor of Metalloproteinases (TIMP-1) and Chitinase-3-like protein 1(YKL-40) in serum(12 Month)
- Sensitivity and specificity of non-invasive marker at the baseline in comparison to liver biopsy as a gold standard(12 Month)
- Changes on FibroScan-measurement (LSM) and serum parameter(6,12,18,24,36,48 and 60 month)
- Quota of patients with normalization of Alanine transaminase(ALT)-measurement in blood at separate timepoints(6,12, 18, 24, 32, 48 and 60 month)
- Decrease of hepatitis B virus-DNA and quota of patients with non-detectable hepatitis B virus-DNA at separate timepoints.(6, 12, 18, 24, 32, 48 and 60 month)
- Incidence of side effects(60 month)
- Quota of patients with hepatitis B viral protein loss, antibodies to the the hepatitis B 'e' antigen seroconversion, surface antigen of the Hepatitis-B-Virus loss and antibodies to the hepatitis B core antigen seroconversion at separate timepoints(6,12, 18, 24, 32, 48 and 60 month)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
4 期
Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis PatientsHepatitis BLiver CirrhosisNCT02849132Beijing Friendship Hospital800
招募中
3 期
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic BurdenAortic Stenosis, SevereNCT05230901University Medical Center Goettingen300
Unknown
不适用
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir TreatmentChronic Hepatitis CNCT02865369Sang Gyune Kim103
已完成
不适用
Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial RespondersHepatitis BNCT00704106Pacific Health Foundation60
尚未招募
2 期
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burdeI50Heart failureDRKS00019893niversitätsmedizin Göttingen150